This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of LJP 394 (Abetimus Sodium) in Lupus Patients

This study has been withdrawn prior to enrollment.
Information provided by:
La Jolla Pharmaceutical Company Identifier:
First received: October 17, 2006
Last updated: August 31, 2015
Last verified: February 2007
The primary purpose of this study is to assess the safety and pharmacodynamic effect of LJP 394 at doses of 100 mg, 300 mg and 900 mg on anti-dsDNA antibody levels in patients with SLE.

Condition Intervention Phase
Systemic Lupus Erythematosus Drug: abetimus sodium (LJP 394) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Diagnostic
Official Title: A Randomized, Double-Blind Study to Evaluate the Safety, Pharmacokinetic and Pharmacodynamic Effects of Abetimus Sodium in Patients With Systemic Lupus Erythematosus (SLE)

Resource links provided by NLM:

Further study details as provided by La Jolla Pharmaceutical Company:

Primary Outcome Measures:
  • The assessment of the safety and pharmacodynamic effect of abetimus sodium at
  • doses of 100mg, 300mg, and 900mg in reducing the anti-dsDNA antibody levels in
  • patients with SLE will be based on laboratory data from the central laboratory
  • and confirmed by supporting data. The pharmacodynamic effic will be assessed
  • using historical placebo effect as a control.

Enrollment: 0
Study Start Date: September 2006
Detailed Description:

Ages Eligible for Study:   12 Years to 70 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or females between 12 and 70 years old.
  • Diagnosis of Systemic Lupus Erythematosus (SLE)
  • Females must be non-pregnant and non-lactating. Females must agree to use adequate birth control methods during the course of the study.
  • Ability to have weekly intravenous (IV) administration of study drug.

Exclusion Criteria:

  • Prior exposure to abetimus sodium within 6 months prior to screening.
  • Patients not on stable medications for 30 days prior to screening.
  • Patients with acute or chronic infections.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00390091

United States, California
Wallace Rheumatic Study Center
Los Angeles, California, United States, 90048
United States, Pennsylvania
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States, 16635
Sponsors and Collaborators
La Jolla Pharmaceutical Company
Study Chair: Matthew D Linnik, PhD La Jolla Pharmaceutical Company
  More Information

Additional Information: Identifier: NCT00390091     History of Changes
Other Study ID Numbers: LJP 394-90-16
Study First Received: October 17, 2006
Last Updated: August 31, 2015

Keywords provided by La Jolla Pharmaceutical Company:
Systemic Lupus Erythematosus
Nephritis, Lupus

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases processed this record on August 18, 2017